These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2166367)

  • 1. Glutamate: a new target in schizophrenia?
    Wachtel H; Turski L
    Trends Pharmacol Sci; 1990 Jun; 11(6):219-20. PubMed ID: 2166367
    [No Abstract]   [Full Text] [Related]  

  • 2. A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine.
    Deutsch SI; Mastropaolo J; Schwartz BL; Rosse RB; Morihisa JM
    Clin Neuropharmacol; 1989 Feb; 12(1):1-13. PubMed ID: 2540909
    [No Abstract]   [Full Text] [Related]  

  • 3. Bench to bedside: the glutamate connection.
    Choi DW
    Science; 1992 Oct; 258(5080):241-3. PubMed ID: 1357748
    [No Abstract]   [Full Text] [Related]  

  • 4. More dimensions for glutamate toxicity.
    Barnes DM
    Science; 1988 Dec; 242(4885):1509-10. PubMed ID: 2904700
    [No Abstract]   [Full Text] [Related]  

  • 5. Schizophrenia: a subcortical neurotransmitter imbalance syndrome?
    Carlsson M; Carlsson A
    Schizophr Bull; 1990; 16(3):425-32. PubMed ID: 1981107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.
    Konradi C; Heckers S
    Pharmacol Ther; 2003 Feb; 97(2):153-79. PubMed ID: 12559388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does modulation of glutamatergic function represent a viable therapeutic strategy in Alzheimer's disease?
    Lawlor BA; Davis KL
    Biol Psychiatry; 1992 Feb; 31(4):337-50. PubMed ID: 1348429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperinnervation of orbital frontal cortex in schizophrenia.
    Deakin JF; Slater P; Simpson MD; Royston MC
    Br J Psychiatry; 1990 Sep; 157():459-60. PubMed ID: 1978787
    [No Abstract]   [Full Text] [Related]  

  • 9. Glutamate and schizophrenia.
    Kornhuber J
    Trends Pharmacol Sci; 1990 Sep; 11(9):357. PubMed ID: 2146789
    [No Abstract]   [Full Text] [Related]  

  • 10. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains.
    Tsai G; Passani LA; Slusher BS; Carter R; Baer L; Kleinman JE; Coyle JT
    Arch Gen Psychiatry; 1995 Oct; 52(10):829-36. PubMed ID: 7575102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutamate receptors and phosphoinositide metabolism: stimulation via quisqualate receptors is inhibited by N-methyl-D-aspartate receptor activation.
    Palmer E; Monaghan DT; Cotman CW
    Brain Res; 1988 Sep; 464(2):161-5. PubMed ID: 2905924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excitatory amino acids and neuropsychiatric disorders.
    Olney JW
    Biol Psychiatry; 1989 Sep; 26(5):505-25. PubMed ID: 2571362
    [No Abstract]   [Full Text] [Related]  

  • 13. Glutamate receptor antagonism: neurotoxicity, anti-akinetic effects, and psychosis.
    Riederer P; Lange KW; Kornhuber J; Jellinger K
    J Neural Transm Suppl; 1991; 34():203-10. PubMed ID: 1687783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics.
    Sherman AD; Hegwood TS; Baruah S; Waziri R
    Biol Psychiatry; 1991 Dec; 30(12):1191-8. PubMed ID: 1686412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutamate and dopamine dysregulation in schizophrenia--a synthesis and selective review.
    Stone JM; Morrison PD; Pilowsky LS
    J Psychopharmacol; 2007 Jun; 21(4):440-52. PubMed ID: 17259207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Glutamate hypothesis of schizophrenia and targets for new antipsychotic drugs].
    Hashimoto K; Iyo M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2002 Feb; 22(1):3-13. PubMed ID: 11917507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decoding schizophrenia.
    Javitt DC; Coyle JT
    Sci Am; 2004 Jan; 290(1):48-55. PubMed ID: 14682038
    [No Abstract]   [Full Text] [Related]  

  • 18. Regionally selective deficits in uptake sites for glutamate and gamma-aminobutyric acid in the basal ganglia in schizophrenia.
    Simpson MD; Slater P; Royston MC; Deakin JF
    Psychiatry Res; 1992 Jun; 42(3):273-82. PubMed ID: 1353892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of anti-idiotypic antibodies as a strategy for studying glutamate receptors.
    Duce IR; Budd TC; Richardson PJ
    Biochem Soc Trans; 1991 Feb; 19(1):143-6. PubMed ID: 1645307
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia.
    Krystal JH; Anand A; Moghaddam B
    Arch Gen Psychiatry; 2002 Jul; 59(7):663-4. PubMed ID: 12090822
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.